Published in World J Gastroenterol on May 14, 2009
Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol (2010) 1.31
APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol (2011) 1.24
Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma. J Med Life (2015) 0.81
FDG-Avid Portal Vein Tumor Thrombosis from Hepatocellular Carcinoma in Contrast-Enhanced FDG PET/CT. Asia Ocean J Nucl Med Biol (2015) 0.76
Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. World J Gastroenterol (2017) 0.75
Portal vein thrombosis with contrast-enhanced ultrasound in a patient with hepatocellular carcinoma: a case study. Australas J Ultrasound Med (2015) 0.75
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Terminology of nodular hepatocellular lesions. Hepatology (1995) 3.87
The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol (2004) 2.18
The role of contrast-enhanced ultrasound in the detection of focal liver leasions. Eur Radiol (2001) 1.65
Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology (1991) 1.63
Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer (1990) 1.61
BR1: a new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbubbles. Invest Radiol (1995) 1.55
Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol (1997) 1.47
Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol (2000) 1.46
Portal vein thrombosis in patients with cirrhosis: does sonographic detection of intrathrombus flow allow differentiation of benign and malignant thrombus? AJR Am J Roentgenol (1995) 1.27
Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging (2007) 1.20
Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma. AJR Am J Roentgenol (1993) 1.20
SonoVue, a new ultrasound contrast agent. Eur Radiol (1999) 1.11
Sonographic features of portal vein thrombosis. AJR Am J Roentgenol (1985) 1.08
Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. AJR Am J Roentgenol (2006) 1.04
Differential diagnosis of hepatocellular nodular lesions. Semin Diagn Pathol (1998) 1.03
Detection of thrombosis in the portal venous system: comparison of contrast-enhanced MR angiography with intraarterial digital subtraction angiography. Radiology (2000) 1.03
Duplex pulsed Doppler sonography of portal vein thrombosis in hepatocellular carcinoma. J Ultrasound Med (1991) 1.01
Portal vein involvement in hepatocellular carcinoma: dynamic CT features. Radiology (1984) 0.98
CT of portal venous occlusion. AJR Am J Roentgenol (1992) 0.94
Diagnosis of portal vein thrombosis in patients with hepatocellular carcinoma: efficacy of color Doppler sonography compared with angiography. AJR Am J Roentgenol (1993) 0.88
Hepatocellular carcinoma. Changing concepts in diagnosis and management. Arch Surg (1984) 0.88
Contrast-enhanced color Doppler US in malignant portal vein thrombosis. Acta Radiol (2000) 0.85
Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. Invest Radiol (2000) 0.85
Conditions favoring long-term survival after hepatectomy for hepatocellular carcinomas. Cancer Chemother Pharmacol (1989) 0.85
Hepatocellular carcinoma presenting only as portal venous tumor thrombosis: CT demonstration. J Comput Assist Tomogr (1992) 0.84
Diagnosis of portal vein tumor thrombus by pulsed Doppler ultrasonography. J Clin Ultrasound (1992) 0.81
Portal vein thrombosis after percutaneous ethanol injection for hepatocellular carcinoma: value of color Doppler sonography in distinguishing chemical and tumor thrombi. AJR Am J Roentgenol (1995) 0.78
Hepatofugal arterial signal in the main portal vein: an indicator of intravascular tumor spread. Radiology (1991) 0.77
Liver hypertrophy and portal hypertension in association with tumor thrombus in the portal vein: CT findings. J Comput Assist Tomogr (1991) 0.77
Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol (2012) 2.18
Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol (2008) 2.00
Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases. Am J Surg Pathol (2003) 1.87
Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol (2004) 1.74
Absence of Helicobacter spp in the liver of patients with primary or metastatic liver cancer. Hepatology (2002) 1.57
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol (2009) 1.50
An unusual cause of dysphagia. J Rheumatol (2012) 1.38
Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med (2011) 1.33
The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol (2011) 1.15
The HOX gene network in hepatocellular carcinoma. Int J Cancer (2011) 1.07
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med (2012) 1.07
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol (2009) 1.06
The HLA-B*2709 subtype in a woman with early ankylosing spondylitis. Arthritis Rheum (2007) 1.04
Diffuse idiopathic skeletal hyperostosis: differentiation from ankylosing spondylitis. Curr Rheumatol Rep (2009) 1.03
Hepatitis C virus-related arthritis. Autoimmun Rev (2008) 1.02
Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy. Am J Gastroenterol (2002) 1.00
Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR Am J Roentgenol (2005) 0.96
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford) (2013) 0.94
Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol (2011) 0.94
Aortitis and periaortitis in ankylosing spondylitis. Joint Bone Spine (2010) 0.92
Validation of an extension of the international non-invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis. J Gastroenterol Hepatol (2011) 0.89
Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma. Leuk Lymphoma (2013) 0.88
The challenge of early diagnosis of psoriatic arthritis. J Rheumatol (2008) 0.87
Prevalence of Undiagnosed Diabetes in Rheumatoid Arthritis: an OGTT Study. Medicine (Baltimore) (2016) 0.86
Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis. J Rheumatol (2009) 0.86
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford) (2010) 0.85
Complications after interventional sonography of focal liver lesions: a 22-year single-center experience. J Ultrasound Med (2003) 0.85
Percutaneous sonographically guided saline-enhanced radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol (2003) 0.85
Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab. Clin Exp Rheumatol (2011) 0.85
Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol (2009) 0.84
Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. J Gastroenterol (2010) 0.83
Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev (2011) 0.83
Role of trauma in psoriatic arthritis. J Rheumatol (2008) 0.82
The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol (2011) 0.81
Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis (2009) 0.81
Low frequency of axial involvement in southern Italian Caucasian children with HLA-B27 positive juvenile onset undifferentiated spondyloarthritis. Clin Exp Rheumatol (2012) 0.80
The HOX genes are expressed, in vivo, in human tooth germs: in vitro cAMP exposure of dental pulp cells results in parallel HOX network activation and neuronal differentiation. J Cell Biochem (2006) 0.80
Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab. Clin Exp Rheumatol (2010) 0.80
Beyond early diagnosis: occult psoriatic arthritis. J Rheumatol (2010) 0.79
Spondyloarthritis with onset after age 45. Curr Rheumatol Rep (2013) 0.79
Spondyloarthritis and diffuse idiopathic skeletal hyperostosis: two different diseases that continue to intersect. J Rheumatol (2013) 0.79
Etanercept in spondyloarthropathies. Part I: current evidence of efficacy. Clin Exp Rheumatol (2011) 0.79
Psoriatic arthritis sine psoriasis. J Rheumatol Suppl (2009) 0.79
Fast spin echo-T2-weighted sequences with fat saturation in toe dactylitis of spondyloarthritis. Clin Rheumatol (2008) 0.79
Late-onset spondyloarthritis: subset that should not be forgotten. J Rheumatol (2012) 0.79
Psoriatic arthritis: pharmacoeconomic considerations. Curr Rheumatol Rep (2009) 0.79
Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab. Clin Exp Rheumatol (2010) 0.79
Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: high-grade dysplastic nodules represent early stages of hepatocellular carcinoma. Lab Invest (2002) 0.79
Effects of a combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a pilot study. J Rheumatol (2006) 0.79
Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. Rheumatol Int (2003) 0.79
Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease. J Rheumatol (2003) 0.78
Helicobacter spp. and liver diseases. Infez Med (2003) 0.78
Pharmacoeconomic issues in psoriatic arthritis. J Rheumatol Suppl (2012) 0.78
An update on the management of hepatitis C virus-related arthritis. Expert Opin Pharmacother (2014) 0.78
Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. J Rheumatol (2009) 0.77
The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost (2016) 0.76
Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs (2010) 0.76
High prevalence of Behçet's disease in southern Italy. Clin Exp Rheumatol (2013) 0.76
Treatment strategies for early psoriatic arthritis. Expert Opin Pharmacother (2009) 0.76
Pharmacological therapy of spondyloarthritis. Expert Opin Pharmacother (2015) 0.76
Rehabilitation for ankylosing spondylitis in the era of biologics: any room left for this treatment? J Rheumatol (2011) 0.76
Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev (2012) 0.76
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]. Recenti Prog Med (2015) 0.76
High Prevalence of Achilles Tendon Enthesopathic Changes in Patients with Type 2 Diabetes Without Peripheral Neuropathy. J Am Podiatr Med Assoc (2016) 0.76
Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis. J Gastroenterol Hepatol (2012) 0.76
The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis. Thromb Haemost (2016) 0.76
Challenges in economic evaluation of psoriatic arthritis. J Rheumatol (2010) 0.75
High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy. Clin Chem Lab Med (2004) 0.75
Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma? World J Gastroenterol (2013) 0.75
Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis. Reumatismo (2013) 0.75
Efficacy of bosentan in the treatment of a patient with mixed connective tissue disease complicated by pulmonary arterial hypertension. Clin Rheumatol (2009) 0.75
Prevalence of Type 2 and Type 1 Diabetes in Psoriatic Arthritis: An Italian Study. J Clin Rheumatol (2022) 0.75
Systemic-onset juvenile idiopathic arthritis and HLA-B27 juvenile-onset undifferentiated spondyloarthritis in the same patient. Clin Exp Rheumatol (2012) 0.75
[Subphrenic abscess during the course of acute brucellosis: diagnosis and treatment with percutaneous sonographically-guided drainage]. Infez Med (2003) 0.75
Ochronotic arthropathy of the spine limited to the thoracic section. Rheumatology (Oxford) (2013) 0.75
Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update. Expert Opin Drug Saf (2013) 0.75
Images in rheumatology. Heel enthesopathy of diffuse idiopathic skeletal hyperostosis resembling enthesitis of spondyloarthritis. J Rheumatol (2010) 0.75
The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis. Clin Exp Rheumatol (2014) 0.75
The radiological assessment of axial involvement in psoriatic arthritis. J Rheumatol Suppl (2012) 0.75
[Diagnostic pathway of an unusual case of nephrotic syndrome: immunotactoid glomerulopathy]. G Ital Nefrol (2010) 0.75
[Prognostic and curative value of sentinel node in breast cancer. A 377 patients experience]. Ann Ital Chir (2010) 0.75
Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case. Anticancer Res (2004) 0.75
New insights in occult psoriatic arthritis. J Rheumatol Suppl (2012) 0.75